Kubisz et al. Journal of Medical Case Reports 2012, 6:350 http://www.jmedicalcasereports.com/content/6/1/350 Page 3 of 4 Figure 1 The time changes in initial inhibitor titer (IT) and factor VIII (FVIII) recovery before and during immune tolerance induction (ITI). IT constantly decreased after the FVIII discontinuation; during ITI, after the initial increase (up to 72.0BU/mL) in the first month (anamnestic response), a constant decrease in IT was seen with a transient low increase (up to 12.0BU/mL) during severe infection (catheter-related sepsis) in the second month; FVIII recovery continuously improved from the fourth month of ITI. BU = Bethesda unit; FVIII = factor VIII; FVIII P = prophylaxis with factor VIII; IT = inhibitor titer; ITI = immune tolerance induction; IU = international unit; rFVIIa = recombinant activated factor VII. prothrombin complex concentrate FEIBA. Both agents are comparable in terms of efficacy and safety. However, the ability of FEIBA to induce anamnestic response, and thus prolong the persistence of inhibitor, is a possible drawback for its use in ITI. Although the negative effect of this phenomenon on ITI outcome is not clear, FEIBA is nowadays not recommended for the first-line treat- ment in patients planned for ITI [13]. In concordance